top of page

Rusfertide's REVIVE Study Highlights 2-Year Efficacy in Polycythemia Vera (PV)

Updated: Jan 19

Protagonist Therapeutics, Inc. has unveiled compelling data from its Rusfertide REVIVE study during the American Society of Hematology 2023 Annual Meeting. The study spans two years, demonstrating the lasting efficacy and safety of rusfertide, a hepcidin mimetic, in treating polycythemia vera (PV) patients. The findings showcase significant benefits, including durable hematocrit control, reduced phlebotomy needs, and overall improved patient outcomes.


Rusfertide's REVIVE Study Highlights 2-Year Efficacy in Polycythemia Vera

Want to read more?

Subscribe to gmpnsf.org to keep reading this exclusive post.

24 views0 comments

Comments

Rated 0 out of 5 stars.
Couldn’t Load Comments
It looks like there was a technical problem. Try reconnecting or refreshing the page.
bottom of page